ArticlePloS one2012
Development and validation of a prognostic gene-expression signature for lung adenocarcinoma.
Article in PloS one, 2012. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 24 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
24 citing papers in PubMed, 39 citations in OpenAlex.
- Multi-Omics Analysis of TYMS as a Prognostic Biomarker and Therapeutic Target for Lung Adenocarcinoma.Cancer medicine · 2026Article
- Identification of Prognosis Signature Based on cGAS-STING Pathway and Its Immunotherapeutic Significance in Lung Adenocarcinoma.Molecular biotechnology · 2026Article
- Molecular Radiobiology in Non-Small Cell Lung Cancer: Prognostic and Predictive Response Factors.Cancers · 2022Review
- Article
- Gene Expression Profiling as a Potential Tool for Precision Oncology in Non-Small Cell Lung Cancer.Cancers · 2021Review
- New Perspectives in Different Gene Expression Profiles for Early and Locally Advanced Non-Small Cell Lung Cancer Stem Cells.Frontiers in oncology · 2021Article
- Identification of a Sixteen-gene Prognostic Biomarker for Lung Adenocarcinoma Using a Machine Learning Method.Journal of Cancer · 2020Article
- Development and Validation of a Seven-Gene Signature for Predicting the Prognosis of Lung Adenocarcinoma.BioMed research international · 2020Article
- Article
- Robust method for identification of prognostic gene signatures from gene expression profiles.Scientific reports · 2017Article
- Generating a robust prediction model for stage I lung adenocarcinoma recurrence after surgical resection.Oncotarget · 2017Article
- Consensus of gene expression phenotypes and prognostic risk predictors in primary lung adenocarcinoma.Oncotarget · 2016Article
- Article
- Article
- Integrating Tumor and Stromal Gene Expression Signatures With Clinical Indices for Survival Stratification of Early-Stage Non-Small Cell Lung Cancer.Journal of the National Cancer Institute · 2015Article
- Identification of a multi-cancer gene expression biomarker for cancer clinical outcomes using a network-based algorithm.Scientific reports · 2015Article
- Intrinsic cancer subtypes--next steps into personalized medicine.Cellular oncology (Dordrecht, Netherlands) · 2015Review
- SPARCoC: a new framework for molecular pattern discovery and cancer gene identification.PloS one · 2015Article
- Low expression of ITIH5 in adenocarcinoma of the lung is associated with unfavorable patients' outcome.Epigenetics · 2015Article
- Genetic basis for clinical response to CTLA-4 blockade in melanoma.The New England journal of medicine · 2014Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
10 authors at 3 institutions in 2 countries.
Funding
Abstract
Although several prognostic signatures have been developed in lung cancer, their application in clinical practice has been limited because they have not been validated in multiple independent data sets. Moreover, the lack of common genes between the signatures makes it difficult to know what biological process may be reflected or measured by the signature. By using classical data exploration approach with gene expression data from patients with lung adenocarcinoma (n = 186), we uncovered two distinct subgroups of lung adenocarcinoma and identified prognostic 193-gene gene expression signature associated with two subgroups. The signature was validated in 4 independent lung adenocarcinoma cohorts, including 556 patients. In multivariate analysis, the signature was an independent predictor of overall survival (hazard ratio, 2.4; 95% confidence interval, 1.2 to 4.8; p = 0.01). An integrated analysis of the signature revealed that E2F1 plays key roles in regulating genes in the signature. Subset analysis demonstrated that the gene signature could identify high-risk patients in early stage (stage I disease), and patients who would have benefit of adjuvant chemotherapy. Thus, our study provided evidence for molecular basis of clinically relevant two distinct two subtypes of lung adenocarcinoma.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.